gastric electrical stimulator enterra® therapy system (Enterra Feed Corporation)
90
Structured Review
Enterra Feed Corporation
gastric electrical stimulator enterra® therapy system
Gastric Electrical Stimulator Enterra® Therapy System, supplied by Enterra Feed Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gastric+electrical+stimulation+system/enterra+gastric+pacemaker/pm38460084-44-8-10
Average 90 stars, based on 1 article reviews
Gastric Electrical Stimulator Enterra® Therapy System, supplied by Enterra Feed Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gastric+electrical+stimulation+system/enterra+gastric+pacemaker/pm38460084-44-8-10
Average 90 stars, based on 1 article reviews
gastric electrical stimulator enterra® therapy system - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Produced:Article Title: Body surface mapping of the stomach: New directions for clinically evaluating gastric electrical activity. Article Snippet: Disorders of gastroduodenal function without an obvious organic cause are common, defined by the Rome IV criteria to include functional dyspepsia, chronic nausea, and vomiting disorders, in addition to belching and rumination disorders.1 Patients must meet criteria based upon symptoms, along with the requirement that no evidence of organic, systemic, or metabolic disease that is likely to explain their symptoms is found on routine investigations (including at upper endoscopy).1 However, other gastric disorders, particularly gastroparesis, may have a clinical picture which is indistinguishable from the functional nausea and vomiting disorders, despite being Received: 10 July 2020 | Revised: 11 October 2020 | Accepted: 3 November 2020 DOI: 10.1111/nmo.14048 Article Title: Ingestible transiently anchoring electronics for microstimulation and conductive signaling. Article Snippet: To mimic the FDA-authorized Article Title: Ingestible transiently anchoring electronics for microstimulation and conductive signaling Article Snippet: To mimic the FDA-authorized In Vivo:Article Title: Body surface mapping of the stomach: New directions for clinically evaluating gastric electrical activity. Article Snippet: Disorders of gastroduodenal function without an obvious organic cause are common, defined by the Rome IV criteria to include functional dyspepsia, chronic nausea, and vomiting disorders, in addition to belching and rumination disorders.1 Patients must meet criteria based upon symptoms, along with the requirement that no evidence of organic, systemic, or metabolic disease that is likely to explain their symptoms is found on routine investigations (including at upper endoscopy).1 However, other gastric disorders, particularly gastroparesis, may have a clinical picture which is indistinguishable from the functional nausea and vomiting disorders, despite being Received: 10 July 2020 | Revised: 11 October 2020 | Accepted: 3 November 2020 DOI: 10.1111/nmo.14048 Article Title: Ingestible transiently anchoring electronics for microstimulation and conductive signaling. Article Snippet: To mimic the FDA-authorized Article Title: Ingestible transiently anchoring electronics for microstimulation and conductive signaling Article Snippet: To mimic the FDA-authorized Ex Vivo:Article Title: Body surface mapping of the stomach: New directions for clinically evaluating gastric electrical activity. Article Snippet: Disorders of gastroduodenal function without an obvious organic cause are common, defined by the Rome IV criteria to include functional dyspepsia, chronic nausea, and vomiting disorders, in addition to belching and rumination disorders.1 Patients must meet criteria based upon symptoms, along with the requirement that no evidence of organic, systemic, or metabolic disease that is likely to explain their symptoms is found on routine investigations (including at upper endoscopy).1 However, other gastric disorders, particularly gastroparesis, may have a clinical picture which is indistinguishable from the functional nausea and vomiting disorders, despite being Received: 10 July 2020 | Revised: 11 October 2020 | Accepted: 3 November 2020 DOI: 10.1111/nmo.14048 Article Title: Ingestible transiently anchoring electronics for microstimulation and conductive signaling. Article Snippet: To mimic the FDA-authorized Article Title: Ingestible transiently anchoring electronics for microstimulation and conductive signaling Article Snippet: To mimic the FDA-authorized Injection:Article Title: Body surface mapping of the stomach: New directions for clinically evaluating gastric electrical activity. Article Snippet: Disorders of gastroduodenal function without an obvious organic cause are common, defined by the Rome IV criteria to include functional dyspepsia, chronic nausea, and vomiting disorders, in addition to belching and rumination disorders.1 Patients must meet criteria based upon symptoms, along with the requirement that no evidence of organic, systemic, or metabolic disease that is likely to explain their symptoms is found on routine investigations (including at upper endoscopy).1 However, other gastric disorders, particularly gastroparesis, may have a clinical picture which is indistinguishable from the functional nausea and vomiting disorders, despite being Received: 10 July 2020 | Revised: 11 October 2020 | Accepted: 3 November 2020 DOI: 10.1111/nmo.14048 Article Title: Ingestible transiently anchoring electronics for microstimulation and conductive signaling. Article Snippet: To mimic the FDA-authorized Article Title: Ingestible transiently anchoring electronics for microstimulation and conductive signaling Article Snippet: To mimic the FDA-authorized |